Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD
定义 LINE-1 逆转录转座子对 AD / ADRD 的分子贡献
基本信息
- 批准号:10518515
- 负责人:
- 金额:$ 77.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease patientAlzheimer&aposs disease related dementiaAstrocytesAutopsyBiologicalBiological AssayBiological ModelsBrainCause of DeathCell AgingCell Culture TechniquesCell NucleusCellsCerebrospinal FluidChromosomal InstabilityChronic stressClinicalCytoplasmic GranulesCytosolDNADNA DamageDNA replication forkDataDetectionDeteriorationDiseaseDouble-Stranded RNAElderlyEndogenous RetrovirusesEnzymesExhibitsFibroblastsFreezingFrontotemporal DementiaFunctional disorderGenesGenomeGenomicsGrowth FactorHomeostasisHumanHybridsImmunityImpaired cognitionIn VitroIndividualInduced pluripotent stem cell derived neuronsInflammationInflammatoryIntegration Host FactorsInterferonsKnowledgeLabelLewy Body DementiaLifeLocationMass Spectrum AnalysisModelingMolecularMolecular GeneticsMotivationMusNeurodegenerative DisordersNeuronsNormal CellNucleic AcidsOnset of illnessParasitesPathologicPathologyPathway interactionsPatientsPhasePhenotypePhysiologicalPlayProductionPropertyProteinsRNARNA InterferenceRNA-Directed DNA PolymeraseRNA-Protein InteractionReactive Oxygen SpeciesResearchRetrotransposonRibonucleoproteinsRoleSamplingSelfish DNAShotgunsSourceSystemTechniquesTissuesTitrationsage relatedage related neurodegenerationagedbasebrain tissuecytokineendonucleaseflygenome integrityimmunogenicimprovedinduced pluripotent stem cellnormal agingoverexpressionpathological agingpreventprotein expressionsenescencetau Proteins
项目摘要
Project Summary: Alzheimer's Disease (AD) and AD-related dementias (ADRDs; e.g. Frontotemporal
Dementia, Lewy Body Dementia, etc.) are crippling neurodegenerative disorders. The onset of these diseases
is strongly correlated with aging. Cures for AD and ADRDs remain elusive; Alzheimer's has become the 6th most
frequent cause of death in the USA. An emerging candidate contributor to Alzheimer's and ADRD is the L1
retrotransposon, which becomes dysregulated during aging and correlates with Alzheimer's / ADRD onset. One
hypothetical mechanism by which L1 may contribute to Alzheimer's / ADRD is through its exacerbation of cellular
senescence. Senescence is a phenomenon by which normal cells stop dividing; these cells accumulate with
advancing age and are found at the locations of dysfunction in age-related diseases. In mice, senescent cells
have been shown to shorten life and actively drive age-related neurodegeneration; preventing senescent cell
accumulation decreases tau-dependent degeneration and cognitive decline. AD patients exhibit increased
indicators of cellular senescence. It is increasingly clear that senescent cells are not inert, but instead drive tissue
deterioration via the senescence-associated secretory phenotype - secreting a variety of growth factors and pro-
inflammatory cytokines. L1 retrotransposons have recently been shown to drive progression of the senescence-
associated secretory phenotype, and thus, L1 is an important agent of cellular senescence. L1 activation is also
associated with AD-related Tau pathologies. The L1 encoded ORF2p enzyme (endonuclease and reverse
transcriptase) is often flagged as a source of pathological cellular insults, e.g. via new, mutagenic L1 insertions
and contributions to chromosomal instability. However, the effects of L1 expression extend beyond DNA
damage. Numerous mechanisms may be at play, including the titration of normally homeostatic host factors
away from their physiologic functions and into L1 ribonucleoprotein granules, as well as the production of
immunity-and-inflammation-triggering cytoplasmic L1 DNA:RNA hybrids; indeed, the latter is now understood to
be a key component of L1’s role in cellular senescence. Moreover, L1 also mobilizes Alu and other non-
autonomous retrotransposons.
Objectives: In Aim 1, we will use targeted mass spectrometry to profile L1 ORF1 protein expression in the
cerebrospinal fluid (CSF) and post-mortem brain tissues of patients exhibiting AD/ADRD and cognitive decline,
as well as in senescent cells and neuronal iPSCs; in Aim 2 (in vitro cell culture) and Aim 3 (clinical samples) we
will profile L1-associated protein-protein and protein-RNA interactions in the same biological samples as Aim 1;
and in Aim 4 we will take a candidate-based approach using molecular genetics to dissect the mechanisms of
action of L1 in senescent cells.
项目概述:阿尔茨海默病(AD)和与AD相关的痴呆(ADRDs);例如额颞叶
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Paul LaCava其他文献
John Paul LaCava的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Paul LaCava', 18)}}的其他基金
Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD
定义 LINE-1 逆转录转座子对 AD / ADRD 的分子贡献
- 批准号:
10701914 - 财政年份:2022
- 资助金额:
$ 77.99万 - 项目类别:
An integrated pipeline for next-generation protein interactomics
下一代蛋白质相互作用组学的集成管道
- 批准号:
10061613 - 财政年份:2017
- 资助金额:
$ 77.99万 - 项目类别:
Monospecific monoclonal antibodies against human protein complexes on an interactome-wide scale.
在相互作用组范围内针对人类蛋白质复合物的单特异性单克隆抗体。
- 批准号:
9202440 - 财政年份:2016
- 资助金额:
$ 77.99万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Collaborative R&D
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
- 批准号:
23K20355 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
- 批准号:
23K24782 - 财政年份:2024
- 资助金额:
$ 77.99万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




